 | Altasciences has expertise in highly sensitive bioanalytical assays development for the quantitation of oligonucleotides in complex biological matrices. | |
 | Biodextris works with mid and large sized vaccine companies to develop, manufacture and test a wide range of biologic products for vaccine, pharmaceutical and other applications. | |
 | CellCarta offers a range of services to support the development of therapeutic modalities, biomarkers and companion diagnostic tests. | |
 | Canadian Alliance for Skills and Training in Life Sciences (CASTL) delivers world-class technical skills development and training in biomanufacturing. | |
 | The CERASP is a centre for technology transfer (CCTT) in the pharmaceutical sciences and connected industries, specializing in supporting businesses from early-stage discovery to scale-up and technical transfer for GMP-ready production to facilitate the commercialization journey. | |
 | CQIB is a life sciences incubator/accelerator offering laboratories and workspaces for start-up companies. | |
| DePTAQ Network | DePTAQ provides provide a full range of services, from the initial design of RNA therapies to preclinical-scale production, formulation and delivery. Managed by IRCM, McGill University and Sherbrooke University. | |
 | ECOGENE-21 is a Canadian nonprofit organization, patient-centered and internationally recognized for its robust experience and expertise in the design, execution, oversight, and monitoring of clinical trials. | |
 | Epitopea, a transatlantic cancer immunotherapy company founded in 2021 between Cambridge (UK), and Montreal (CA), develops ready-to-use RNA-based immunotherapies for the treatment of difficult-to-cure cancers. | |
 | Feldan is a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutic products. | |
 | Galenvs is a specialized precision developer & manufacturer of DNA/RNA oligonucleotides for therapeutics, offering services from proof-of-concept through in vitro validation and pilot-scale production. | |
 | Moderna has developed therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. | |
 | Molecular Forecaster combines world-class computational tools with deep domain expertise to tackle the toughest challenges in early-stage drug discovery. | |
 | Nanofacile accelerates and reduces the risks associated with R&D of lipid nanoparticle-based gene therapies with advanced, easy-to-use technology, which includes encapsulation recipes and an advanced microfluidic device. | |
 | Neopharm Life Sciences offers a comprehensive suite of RNA analysis services designed to support researchers, pharmaceutical and biotech companies at every stage of the product development lifecycle, from early discovery to commercial launch and beyond. | |
 | NMX, a contract research partner, supports drug discovery targeting biological macromolecules of therapeutic interest. | |
 | Polaris Oligonucleotides is a Canadian-based biopharma services provider dedicated to advancing oligonucleotides science by leveraging cutting-edge synthetic chemistry. | |
 | Providence Therapeutics is an mRNA Medicines Platform company with over nine years of expertise, a proven mRNA Medicines Platform, a next-generation lipid nanoparticle (LNP) technology and can produce vaccines and therapeutics ranging from personalized to pandemic scales. | |
 | RNA Technologies and Therapeutics Inc. (RNA T&T) is a privately held company headquartered in Montreal, Canada. It specializes in designing, optimizing, and small to medium-scale production (mg to g) of RNA. | |
 | Rynd Biotech specializes in providing accurate, point-of-care testing solutions and discreet at-home testing. Its innovative technology aims to redefine STI management by automating diagnosis and prescription delivery upon positive test results. | |
 | Solstar Pharma has developed an siRNA platform technology using proprietary modified nucleic acid chemistry to inhibit pathogen replication or block the production of cancer-causing proteins. | |
 | For 25 years, TransBIOTech has been accelerating the preclinical development of new therapies by offering the expertise required for drug discovery: pharmacology, cellular and molecular biology, immunology, biochemistry, pharmacokinetics and toxicology. Member of the CCTT network. | |
 | WhiteLab Genomics develops and leverages its proprietary AI platform to accelerate and optimize genomic medicine research and development (gene, cell, and RNA therapies). | |
